Detalhe da pesquisa
1.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407001
2.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Blood
; 142(8): 687-699, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37390310
3.
N-Glycosylation of the Ig Receptors Shapes the Antigen Reactivity in Chronic Lymphocytic Leukemia Subset #201.
J Immunol
; 211(5): 743-754, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37466373
4.
Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib.
Br J Haematol
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634256
5.
Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia.
Eur J Immunol
; 53(10): e2350418, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37561992
6.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood
; 139(22): 3278-3289, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196370
7.
Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Blood
; 140(22): 2348-2357, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921541
8.
Genomic profiling for clinical decision making in lymphoid neoplasms.
Blood
; 140(21): 2193-2227, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001803
9.
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Blood
; 139(5): 732-747, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34653238
10.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Blood
; 140(11): 1229-1253, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653592
11.
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia.
Semin Cancer Biol
; 84: 329-338, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35090979
12.
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target.
J Cell Mol Med
; 27(4): 576-586, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36747338
13.
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
Br J Haematol
; 203(3): 416-425, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580908
14.
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Blood
; 137(23): 3165-3173, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33861303
15.
Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.
Blood
; 137(14): 1895-1904, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33036024
16.
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Future Oncol
; 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36617990
17.
IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling.
Proc Natl Acad Sci U S A
; 117(8): 4320-4327, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32047037
18.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810754
19.
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
Br J Haematol
; 198(1): 103-113, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35277855
20.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676628